We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Returning to health?

5 November 2009 By Lauren Silva

The private equity firm is leading a buyout of drugs market research company IMS. But oldstyle LBO financing is missing. The buyers are putting in a whopping 40% as equity. The rest is coming courtesy of Goldman and mostly from funds it manages, not its own balance sheet.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)